P0334: AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjectsECCO'25Year: 2025
Authors: Sáez-Borderías, A.(1)*;Van Kaem, T.(2);Alberti, J.(3);Stiers, P.J.(2);Sabadie, C.(4);Van Heeswijk, R.(4);Senso, T.(1);Pampín, B.(5);Bosser, R.(6);Wiesel, P.(7);
(1)Agomab Spain S.L.U, Development, A Coruña, Spain;(2)Agomab Therapeutics NV, Clinical Development, Antwerp, Belgium;(3)DMPK consultant, Analysis, Barcelona, Spain;(4)Agomab Therapeutics NV, Development, Antwerp, Belgium;(5)Agomab Spain S.L.U, Research, A Coruña, Spain;(6)formerly Agomab Spain S.L.U, Development, A Coruña, Spain;(7)Agomab US- Inc, Clinical Development, Cambridge, United States;
Rodon J, Carducci M, Sepulveda-Sanchez JM, et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs (2015) 33:357-370.
Jung SY, Hwang S, Clarke JM, et al. Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Invest New Drugs (2020) 38:812-820.
P0335: Development of an entrustable professional activity for intestinal ultrasound in North AmericaECCO'25Year: 2025
Authors: Aronskyy, I.(1);Spencer, E.(2);Yen, E.(3);Chugh, R.(4);Winter, M.(5);Jacobs, J.(6);Wahbeh, G.(7);Debruyn, J.(8)*;
(1)Mount Sinai, Division of General Internal Medicine, New York, United States;(2)Mount Sinai, Division of Pediatric Gastroenterology and Nutrition, New York, United States;(3)Northwestern Feinberg School of Medicine, Division of Gastroenterology and Hepatology, Chicago, United States;(4)University of California San Francisco, Division of Gastroenterology, San Francisco, United States;(5)Geisel School of Medicine at Dartmouth, Division of Gastroenterology and Hepatology, Lebanon, United States;(6)University of Washington, Division of Gastroenterology, Seattle, United States;(7)University of Washington, Division of Pediatric Gastroenterology and Hepatology, Seattle, United States;(8)University of Calgary, Division of Pediatric Gastroenterology and Hepatology, Calgary, Canada;
P0336: From inflammation to depression: key biomarkers for Inflammatory Bowel Disease-related Major Depressive DisorderECCO'25Year: 2025
Authors: Hu, C.(1)*;Guo, H.(1);
(1)Chongqing General Hospital, Department of Gastroenterology, Chongqing, China;
[1]Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474:307-317.
[2]Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. J Psychosom Res. 2016; 87:70-80.
P0337: Incidentally Diagnosed Inflammatory Bowel Disease: Prevalence and Long-Term OutcomesECCO'25Year: 2025
Authors: Tubal Bronze, S.M.(1)*;Shenoy, S.(2);Agrawal, M.(3);Colombel, J.F.(3);Rodríguez-Lago, I.(4);Ungaro, R.C.(3);
(1)Hospital Santa Maria, Gastroenterology and Hepatology Department, Lisbon, Portugal;(2)Icahn School of Medicine at Mount Sinai, Department of Hospital Medicine- Department of Medicine, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology- Department of Medicine, New York, United States;(4)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Inflammatory Bowel Disease Unit- Gastroenterology Department, Bilbao, Spain;
P0338: Early identification of pediatric inflammatory bowel disease based on machine learning with non-invasive dataECCO'25Year: 2025
Authors: Wu, H.(1)*;Sun, Y.H.(2);Tang, Z.F.(1);Qin, X.J.(2);Wang, Y.H.(1);Huang, Y.(1);
(1)Children’s Hospital of Fudan University- National Children’s Medical Center, Department of Gastroenterology, Shanghai, China;(2)Children’s Hospital of Fudan University- National Children’s Medical Center, Department of Ultrasound, Shanghai, China;
P0340: Endo-Histo Foundational Fusion Model: A Novel Artificial Intelligence Approach for Predicting Histologic Remission and Early Response to Therapy in a Phase 2 Ulcerative Colitis Clinical TrialECCO'25Year: 2025
Authors: Iacucci, M.(1)*;Santacroce, G.(1);Meseguer, P.(2,3);Del Amor, R.(2);Diéguez, A.(2);Kolawole, B.B.(4);Chaudhuri, U.(4);Zammarchi, I.(1);Hayes, B.(5);Crotty, R.(5);Zardo, D.(6);Maeda, Y.(1);Puga-Tejada, M.(1);Ditonno, I.(1);Vadori, V.(4);Burke, L.(5);Gottlieb, K.T.(7);Owen, C.(7);Eastman, W.J.(7);Ghosh, S.(1);Grisan, E.(4);Naranjo, V.(2);
(1)University College Cork, APC Microbiome Ireland- College of Medicine and Health, Cork, Ireland;(2)Universitat Politècnica de València, Instituto Universitario de Investigación e Innovación en Tecnología Centarada en el Ser Humano- HUMAN-tech, Valencia, Spain;(3)Universitat Politècnica de València, valgrAI – Valencian Graduate School and Research Network of Artificial Intelligence, Valencia, Spain;(4)London South Bank University, School of Engineering, London, United Kingdom;(5)Cork University Hospital, Department of Histopathology, Cork, Ireland;(6)San Bortolo Hospital, Department of Pathology, Vicenza, Italy;(7)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;
P0341: Variation in healthcare utilisation amongst IBD care centres in Australia and New Zealand, Crohn’s Colitis Care Data Insight’s Program.ECCO'25Year: 2025
Authors: Su, W.K.(1,2,3);Wilson, W.(4);Wark, G.(1);Walker, G.(5,6,7);Su, H.(8);Forbes, A.(9);Kim, A.(10,11);Giles, E.(12,13,14);Lawrance, I.(15,16);Dutt, S.(17);Brett, L.(18);Begun, J.(19,20);Lynch, K.(21,22);Andrews, J.M.(3,21,22);Connor, S.J.(1,3,23)*;
(1)Liverpool Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(2)The Ingham Institute for Applied Medical Research, Gastroenterology and Hepatology, Liverpool, Australia;(3)Crohn's Colitis Cure, CCCure, Sydney, Australia;(4)Lyell McEwin Hospital, Department of Anaesthesia, Adelaide, Australia;(5)Royal Brisbane and Women's Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia;(6)QIMR Berghofer, Gut Health, Brisbane, Australia;(7)University of Queensland, Faculty of Medicine, Brisbane, Australia;(8)Te Whatu Ora Health Waitaha Canterbury, Department of Gastroenterology, Christchurch, New Zealand;(9)University of Otago, Department of Medicine, Christchurch, New Zealand;(10)St Vincent's Public Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(11)University of New South Wales, St Vincent's Clinical School, Sydney, Australia;(12)Monash Children's Hospital, Department of Paediatric Gastroenterology, Melbourne, Australia;(13)Hudson Institute of Medical Research, Centre for innate immunity and infectious diseases, Clayton, Australia;(14)Monash University, Department of Paediatrics, Clayton, Australia;(15)Saint John of God Subiaco Hospital, Centre for Inflammatory Bowel Disease, Subiaco, Australia;(16)University of Western Australia, School of Medicine and Pharmacology, Murdoch, Australia;(17)Speciality of Child and Adolescent Health- Children's Hospital at Westmead Clinical School- Sydney School of Medicine- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;(18)Logan Hospital, Department of Gastroenterology, Brisbane, Australia;(19)Mater Hospital Brisbane-, Department of Gastroenterology and Hepatology, Queensland, Australia;(20)The University of Queensland, Mater Research- Faculty of Medicine, Brisbane, Australia;(21)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;(22)University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(23)University of New South Wales, Medicine & Health- South Western Sydney Clinical School, Sydney, Australia;
P0342: Quantitative faecal immunochemical test (qFIT) is comparable to calprotectin as a biomarker of IBD: Prospective longitudinal analysis of disease activity and endoscopic mucosal healingECCO'25Year: 2025
Authors: Cartlidge, P.(1)*;Le-Saint Grant , A.(1);Siu-Ying Lau, P.(1);Hodge, M.(1);Hall, R.(2);Strachan, J.(3);Chuah, S.(4);Whelan, R.(1);Ong, S.(1);Brownson, E.(5);Campbell, I.(5);Poulose , B.(6);Oddy, A.(6);MacDonald, J.(7);Seenan, J.P.(5);Gaya, D.(7);Mowat, C.(2);Ho, G.T.(1);
(1)University of Edinburgh, Institute for Regeneration and Repair, Edinburgh, United Kingdom;(2)Ninewells Hospital, Gastroenterology, Dundee, United Kingdom;(3)Ninewells Hospital, Blood Sciences, Dundee, United Kingdom;(4)University of Glasgow, School of Infection and Immunity, Glasgow, United Kingdom;(5)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(6)Western General Hospital, Gastroenterology, Edinburgh, United Kingdom;(7)Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom;
*AUC – Area Under Curve **HBI-Harvey Bradshaw Index ***SCCAI – Simple Colitis Activity Index
P0343: Gender Identity and Inflammatory Bowel Disease: The Patient PerspectiveECCO'25Year: 2025
Authors: Colwill, M.(1,2)*;Jacob, K.(1);Pollok, R.(2);Poullis, A.(2);
(1)St George's University Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)City St George's- University of London, Gastroenterology, London, United Kingdom;
1. Crohn’s disease and ulcerative colitis in the UK. [Internet]. Available from: https://crohnsandcolitis.org.uk/news-stories/news-items/new-research-shows-over-1-in-123-people-in-uk-living-with-crohn-s-or-colitis
2. Crohn’s & Colitis UK [Internet]. [cited 2024 Oct 2]. Available from: https://crohnsandcolitis.org.uk
P0344: Comparative analysis of a simple POPSIL score with Lémann Index to define the burden of organ damage in Crohn’s disease.ECCO'25Year: 2025
Authors: Ong, S.(1)*;Grant , R.(2);Cartlidge, P.(1);Campbell, I.(3);Hall, R.(4);MacDonald, J.(5);Seenan, J.P.(3);Mowat, C.(4);Chuah, C.S.(6);Kalla, R.(1);Ho, G.T.(1);
(1)University of Edinburgh, Institute for Regeneration and Repair, Edinburgh, United Kingdom;(2)Western General Hospital, Gastroenterology, Edinburgh, United Kingdom;(3)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(4)Ninewells Hospital, Gastroenterology, Dundee, United Kingdom;(5)Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom;(6)University of Glasgow, School of Infection and Immunity, Glasgow, United Kingdom;
1) Pariente B, Torres J, Burisch J, et al. Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. Gastroenterology. 2021 Sep;161(3):853-864.e13
P0345: Tailoring Crohn’s disease surveillance in clinical remission: new insights from the Lewis scoreECCO'25Year: 2025
Authors: Ferreira, A.I.(1,2,3)*;Lima Capela, T.(1,2,3);Xavier, S.(1,2,3);Arieira, C.(1,2,3);Rosa, B.(1,2,3);Cotter, J.(1,2,3);
(1)Unidade Local de Saúde do Alto Ave, Gastroenterology Department, Guimarães, Portugal;(2)School of Medicine- University of Minho, Life and Health Sciences Research Institute ICVS, Braga, Portugal;(3)PT Government Associate Laboratory, ICVS/3B’s, Guimarães/Braga, Portugal;
P0346: Pouch Fistulas: Experience From a Tertiary CenterECCO'25Year: 2025
Authors: Tubal Bronze, S.M.(1)*;Wong, S.Y.(2);Waite, H.(3);Plietz, M.(3);Hahn, S.(4);Greenstein, A.(4);Sylla, P.(4);Khaitov, S.(4);Colombel, J.F.(3);Kayal, M.(3);
(1)Hospital Santa Maria, Gastroenterology and Hepatology Department, Lisbon, Portugal;(2)Icahn School of Medicine at Mount Sinai-, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(3)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(4)Icahn School of Medicine at Mount Sinai, Department of Surgery, New York, United States;
P0347: Correlation between histologic disease activity in the distal and proximal colon in Ulcerative Colitis: A flexible sigmoidoscopy is insufficient to assess histologyECCO'25Year: 2025
Authors: De Marco, D.(1)*;Meadler Kron, C.(2);Marcus, V.(2);Bitton, A.(1);Lakatos, P.(1);Wild, G.(1);Afif, W.(1);Bessissow, T.(1);
(1)McGill University, Gastroenterology and Hepatology, Montreal, Canada;(2)McGill University, Pathology, Montreal, Canada;
P0348: Ultrasound enterography with a novel ultrasound contrast agent for Crohn's DiseaseECCO'25Year: 2025
Authors: Gjengstoe, A.J.(1)*;Volkmann, H.L.V.(1);Aziz, A.(2);Dimcevski, G.(3);Gilja, O.H.(1);Nylund, K.(1);
(1)Haukeland University Hospital, Medical Department, Bergen, Norway;(2)Deaconess Home Hospital Haraldsplass, Medical Department, Bergen, Norway;(3)Kanalspesialistene, Kanalspesialistene, Bergen, Norway;
1. Van Deen WK et. Al. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1742-1750.e7. doi: 10.1016/j.cgh.2015.10.035.
P0349: Gasdermin D: A New Inflammatory Biomarker in Assessing Clinical Disease Activity in Crohn’s DiseaseECCO'25Year: 2025
Authors: Buldukoglu , O.C.(1);Ocal , S.(1);Atar , G.E.(1);Kaya , B.(1);Isik , M.D.(1);Aydin Tigli , G.(2);Akca , S.(1);Akbay Harmandar , F.(1);Cekin , Y.(2);Cekin , A.H.(1)*;
(1)Antalya Training and Research Hospital, Gastroenterology, Antalya, Turkey;(2)Antalya Training and Research Hospital, Medical Microbiology, Antalya, Turkey;
1. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nat Rev Dis Primers. 2020 Apr 2;6(1):22.
2. Dai Z, Liu WC, Chen XY, Wang X, Li JL, Zhang X. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors. Front Immunol. 2023 May 18;14:1178662.
3. Zhang S, Liang Y, Yao J, Li DF, Wang LS. Role of Pyroptosis in Inflammatory Bowel Disease (IBD): From Gasdermins to DAMPs. Front Pharmacol. 2022 May 23;13:833588.
4. Gao X, Wang C, Shen XT, Li CY, Li YC, Gao H, et al. Pyroptosis burden is associated with anti-TNF treatment outcome in inflammatory bowel disease: new insights from bioinformatics analysis. Sci Rep. 2023 Sep 22;13(1):15821.
P0350: Asia Pacific Association of Gastroenterology consensus statements on histopathological evaluation of Inflammatory Bowel DiseasesECCO'25Year: 2025
Authors: Leong, R.(1);Chaemsupaphan, T.(2)*;Lin, H.(3);Lim, W.C.(3);Ooi, C.J.(4);Chetwood, J.D.(1);Mao, R.(5);Wu, H.Y.(6);Wei, S.C.(7);Makharia, G.(8);Ahuja, V.(8);Banerjee, R.(9);Limsrivilai, J.(2);Aniwan, S.(10);Pisespongsa, P.(11);Hilmi, I.(12);Raja Ali, R.A.(13);Leung, W.K.(14);Ng, S.(15);Ye, B.D.(16);Kobayashi, T.(17);Matsuoka , K.(18);Chau, C.(19);Sanpavat, A.(20);Shun, C.T.(21);Puspanathan , P.(22);Gearry, R.B.(23);Danese, S.(24);Ma, C.(25);Pudipeddi, A.(1);Paramsothy, S.(1);
(1)Concord Repatriation General Hospital, Gastroenterology and Liver Services, Sydney, Australia;(2)Siriraj Hospital Mahidol University, Medicine, Bangkok, Thailand;(3)Tan tock Seng hospital, Gastroenterology, Singapore, Singapore;(4)Duke-NUS Medical School, Gastroenterology, Singapore, Singapore;(5)First Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China;(6)National Taiwan University Hospital Jinshan branch, Internal Medicine, New Taipei, Taiwan;(7)National Taiwan University Hospital, Internal Medicine, Taipei, Taiwan;(8)All India institute of Medical Sciences, Gastroenterology and Human Nutrition, New Delhi, India;(9)Asian Institute of Gastroenterology, Gastroenterology, Hyderabad, India;(10)Chulalongkorn University and King Chulalongkorn Memorial Hospital, Gastroenterology, Bangkok, Thailand;(11)King Mongkut's Institute of Technology Ladkrabang, Medicine, Bangkok, Thailand;(12)University Malaya, Medicine, Kuala Lumpur, Malaysia;(13)Sunway University, Medicine, Subang Jaya, Malaysia;(14)Li Ka Shing Faculty of Medicine- The University of Hong Kong, Medicine, Hong Kong, Hong Kong- China;(15)State Key Laboratory of Digestive Disease- Li Ka Shing Institute of Health Sciences- Institute of Digestive Disease- The Chinese University of Hong Kong, Medicine and Therapeutics, Hong Kong, Hong Kong- China;(16)Asan Medical Center- University of Ulsan College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;(17)Kitasato University Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(18)Toho University Sakura Medical Center, Internal Medicine, Chiba, Japan;(19)Tan Tock Seng Hospital, Pathology, Singapore, Singapore;(20)Chulalongkorn University, Pathology, Bangkok, Thailand;(21)National Taiwan University Hospital, Forensic Medicine and Pathology, Taipei, Taiwan;(22)Hospital Pulau Pinang, Pathology, Penang, Malaysia;(23)University of Otago, Medicine, Christchurch, New Zealand;(24)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(25)Cumming School of Medicine- University of Calgary, Medicine, Calgary, Canada;
P0351: Differential Cutoff Values of Fecal Calprotectin Based on Disease Extent of Ulcerative ColitisECCO'25Year: 2025
Authors: Lee, J.(1)*;Kim, S.J.(2);Lee, M.H.(3);
(1)College of Medicine- Chosun University, Divisoin of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(2)College of Medicine- Chosun University, Division of gastroenterology- Department of Internal medicine, Gwangju, Korea- Republic Of;(3)College of Medicine- Chosun univeristy, Division of gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;
1. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Infamm Bowel Dis. 2010;16:338–46.
2. Lee J. [Fecal Calprotectin in Inflammatory Bowel Disease]. Korean J Gastroenterol. 2016 May 25;67(5):233-7.
3. Walsh A, Kormilitzin A, Hinds C, et al. Defning faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis—a prospective analysis. J Crohn’s Colitis. 2019;13:424–30.
4. Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun;110(6):802-19
5. Sonoyama H, Kawashima K, Ishihara S, et al. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr. 2019 May;64(3):265-270
P0352: Fecal calprotectin and pseudopolyps in Ulcerative Colitis: Is there a relationship?ECCO'25Year: 2025
Authors: Crespo, A.(1)*;Pèlach, A.(2);Vidal, M.(2);Calafat, M.(2);Llaó, J.(2);Domènech, E.(2);Mañosa, M.(2);
(1)Dénia Hospital, Gastroenterology Department, Dénia, Spain;(2)Germans Trias i Pujol University Hospital, Gastroenterology Department, Badalona, Spain;
P0353: Correlation between qUality of life and point of cAre intestinaL ultrasound In patients wiTh inflammatorY bowel disease (CUALITY)ECCO'25Year: 2025
Authors: Parra Izquierdo, L.V.(1,2,3)*;Ernest Suarez , K.(4);Argollo, M.(5);Frías-Ordoñez, J.(6);Orduz, G.(7);Puentes Manosalva, F.(8);Cubillos, S.(9);Verstockt , B.(1,3);
(1)KU Leuven Department of Chronic Diseases and Metabolism- Translational Research Center for Gastrointestinal Disorders TARGID, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)Hospital Internacional de Colombia, Gastroenterology and Rheumatology, Bucaramanga, Colombia;(3)University Hospitals Leuven- Department of Gastroenterology and Hepatology- KU Leuven, Gastroenterology, Leuven, Belgium;(4)School of Medicine- University of Costa Rica, Gastroenterology, San Jose, Costa Rica;(5)Universidade Federal de São Paulo, Gastroenterology, Sao Paulo, Brazil;(6)National University of Colombia, Gastroenterology, Bogotá, Colombia;(7)Hospital Internacional de Colombia, Center of Excellence in IBD, Bucaramanga, Colombia;(8)Unión de Cirujanos. ODO. Zentria Salud -Universidad de Caldas, Gastroenterology, Manizales, Colombia;(9)Hospital Internacional de Colombia, Radiology, Bucaramanga, Colombia;
P0354: Mild cognitive impairment occurs in patients with inflammatory bowel disease irrespective of disease activityECCO'25Year: 2025
Authors: Compare, D.(1);Sgamato, C.(1);Minieri, S.(1)*;Marchitto, S.A.(1);Cinque, S.(1);Ambrosio, C.(1);Zerella, G.(1);Nardone, G.(1);
(1)University Federico II of Naples, Department of Clinical Medicine and Surgery- Gastroenterology, Naples, Italy;